BIOMAT Database Logo BIOMAT Database Logo

Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India. 2007

Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
HIV/AIDS Division, Tuberculosis Research Centre (Indian Council of Medical Research), Chennai, India.

OBJECTIVE A variety of demographic factors, sex, and degree of immunosuppression can influence antiretroviral drug concentrations. The authors studied the influence of immune status, sex, and body mass index (BMI) on the steady-state pharmacokinetics of nevirapine delivered as a fixed-dose combination in HIV-1-infected patients in India. METHODS Twenty-six HIV-1-infected adult patients undergoing treatment with nevirapine-based highly active antiretroviral therapy regimens participated in the study. Pharmacokinetic variables were compared between patients divided based on CD4 cell counts, sex, and BMI. RESULTS Patients with higher BMI had lower peak and trough concentration and exposure of nevirapine than those with lower BMI; none of the differences in the pharmacokinetic variables of nevirapine between the various patient groups was statistically significant. CONCLUSIONS Patients' immune status, sex, or BMI had no impact on the pharmacokinetics of nevirapine. Plasma nevirapine concentrations were maintained within the therapeutic range of the drug in the majority of the patients.

UI MeSH Term Description Entries
D007194 India A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. The capitol is New Delhi. Republic of India
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019829 Nevirapine A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. BI-RG-587,Nevirapine Hemihydrate,Viramune,BI RG 587,BIRG587,Hemihydrate, Nevirapine

Related Publications

Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
May 2000, AIDS (London, England),
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
May 2015, The Journal of antimicrobial chemotherapy,
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.
December 2017, Antimicrobial agents and chemotherapy,
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
November 2010, Journal of acquired immune deficiency syndromes (1999),
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
December 2012, Pharmacogenetics and genomics,
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
October 2007, European journal of clinical pharmacology,
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients.
June 2012, Chinese medical journal,
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
January 2008, PloS one,
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
July 2014, The Pediatric infectious disease journal,
Geetha Ramachandran, and A K Hemanthkumar, and S Rajasekaran, and C Padmapriyadarsini, and G Narendran, and S Anitha, and Sudha Subramanyam, and V Kumaraswami, and Soumya Swaminathan
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
November 2004, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!